MedTrace Logo

A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors

NCT04673942 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2024-10-26

No results posted yet for this study

Summary

AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.

Conditions

  • Solid Tumor, Adult
  • Cancer
  • Neoplasms
  • Sarcoma
  • Sarcoma,Soft Tissue
  • Chondrosarcoma

Interventions

BIOLOGICAL

AdAPT-001

Oncolytic virus administered by intratumoral injection

DRUG

Checkpoint Inhibitor, Immune

Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability

Sponsors & Collaborators

  • EpicentRx, Inc.

    lead INDUSTRY

Principal Investigators

  • Bryan Oronsky, MD PhD · EpicentRx, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-29
Primary Completion
2025-12-01
Completion
2027-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04673942 on ClinicalTrials.gov